Under PLX 4032 treatment, drug-resistant melanoma cells exhibited increased nuclear accumulation of YAP/TAZ and transcriptional activity, which, in turn, conferred resistance to BRAF inhibitors in BRAF V600E mutant melanoma cells [68]. Here, BRAF is linked to melanoma.